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Background In SLE, musculoskeletal manifestations have an
impact on quality of life, disability and clinical trial outcomes,
but are harder to assess than in RA and PsA. We previously
showed that joint swelling lacks sensitivity, specificity and
responsiveness compared to ultrasound. USEFUL was a multi-
centre longitudinal study to determine clinical features predict-
ing ultrasound synovitis and whether patients with ultrasound
synovitis respond better to therapy.
Methods SLE patients were recruited if the referring physician
deemed they had inflammatory pain warranting treatment.
Swollen joints were not required. At baseline, physicians
recorded the features that led them to diagnose inflammatory
pain and features of concurrent fibromyalgia and osteoarthri-
tis. Stable doses of prednisolone (£5 mg/day), antimalarials or
immunosuppressants were allowed. Participants received depo-
medrone 120 mg IM then were assessed at 0, 2 and 6 weeks
for 66/68 swollen and tender joint counts, BILAG-2004, SLE-
DAI-2K, physician global and MSK-VAS, inflammatory
markers, patient pain and disease activity-VAS, HAQ-DI,
LupusQoL, ultrasound of hands and wrists (blinded to patient
and clinical assessor). An internal pilot determined the primary
endpoint: EMS-VAS at 2 weeks (adjusted for baseline) between
patients with ultrasound-synovitis vs. normal ultrasound at
baseline. Sensitivity analyses adjusted for prednisolone and
immunosuppressants.
Results 122/133 patients recruited completed all visits. There
was significant disagreement between clinical examination and
ultrasound. 78/133 had ultrasound synovitis; 68% of these
had 1 swollen joint. Of 66/133 patients with  1 swollen
joint, 20% had normal ultrasound.
Ultrasound-synovitis was more likely with joint swelling, a
symmetrical small joint distribution and active serology. Physi-
cian-determined EMS, other lupus features or prior response
to therapy were not associated. Fibromyalgia or osteoarthritis
did not reduce the probability of ultrasound synovitis.
In the full analysis set (n=133) there was no difference in
EMS VAS at 2 weeks according to ultrasound synovial status as
baseline (difference -8 mm, 95% CI -19, 4 mm, p=0.178). 32
patients had fibromyalgia. After excluding these patients, we
found a statistically and clinically significantly better clinical
response to depomedrone in patients with ultrasound-synovitis
at baseline (baseline-adjusted EMS VAS at 2 weeks -12 mm,
95% CI -24, 0 mm, p=0.049). This difference was greater in
the treatment-adjusted sensitivity analysis (-12.8 (95% CI -22, -3
mm), p=0.007) and the per-protocol-adjusted sensitivity analysis
(-14.8 mm (95% CI -20.8, -8.8 mm), p<0.001). Patient with
ultrasound synovitis had higher rates of improvement in the
musculoskeletal BILAG-2004 (56% vs. 26%, p=0.09) and SLE-
DAI-2K (37% vs. 15%, p=0.03).
Conclusions In lupus arthritis distribution and serology, but
not other features, help identify ultrasound-synovitis. Ultra-
sound-synovitis was independent of features of fibromyalgia,
but fibromyalgia confounded assessment of response. Exclud-
ing fibromyalgia, response to therapy was better in patients
with abnormal ultrasound compared to normal. Ultrasound
should be used to select patients for therapy and clinical trials,
especially when there are inflammatory symptoms without
swollen joints.
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